Benitec Biopharma Inc. (BNTC) Stock

Benitec Biopharma Inc. (BNTC) is a Healthcare stock trading at $12.18 (as of 2026-06-18), with a market capitalization of $363.47M and a trailing P/E of -9.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Benitec Biopharma Inc. is a biotechnology company developing genetic medicines, including DNA-directed RNA interference therapeutics for chronic and life-threatening human conditions. Its pipeline includes BB-301, an adeno-associated virus gene therapy for oculopharyngeal muscular dystrophy, and BB-103 for chronic hepatitis B.

Valuation — source: SEC EDGAR (first-party)
Price$12.18
Market Cap$363.47M
P/E Ratio-9.8
EV / EBITDA-3.7
Price / Book2.10
DCF Value (model)$-11.58
DCF Upside vs Price-195.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Return on Equity-26.7%
Current Ratio56.82
Valuation vs Sector & Industry
Stock P/E-9.8
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-147.0%
vs Industry-157.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSUVRETTA CAPITAL MANAGEMENT, LLC ($122.99M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJerel A. Banks
Employees16
CountryUS
IPO Date2014-06-24

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Allogene Therapeutics, Inc. (ALLO)
  • Neumora Therapeutics, Inc. Common Stock (NMRA)
  • Aldeyra Therapeutics, Inc. (ALDX)
  • Candel Therapeutics, Inc. (CADL)
  • Lifecore Biomedical, Inc. (LFCR)
  • Jyong Biotech Ltd. Ordinary Shares (MENS)
  • Foghorn Therapeutics Inc. (FHTX)
  • Puma Biotechnology, Inc. (PBYI)
BNTC earnings history · BNTC institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.